Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recom

Editas Medicine, Inc. (NASDAQ:EDIT – Get Free Report) has received a consensus recommendation of “Hold” from the fourteen ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and seven have assigned a buy recommendation to the company. […]

Related Keywords

Montreal , Quebec , Canada , Baisong Mei , Stifel Nicolaus , Nasdaq , Us Bancorp , Financial Services Group Inc , Securities Exchange Commission , Editas Medicine Inc , Metlife Investment Management , Cantor Fitzgerald , York Mellon Corp , Editas Medicine , Get Free Report , Exchange Commission , New York Mellon Corp , Services Group , Montreal Can , Life Investment Management , Get Free , Leber Congenital Amaurosis , Editas Medicine Daily , Nasdaq Edit , Credit , Medical , Ratings , Consensus ,